Janssen’s Ponesimod Finds Success in Head-to-Head Multiple Sclerosis Trial

In a Phase III head-to-head trial, Janssen Pharmaceutical’s ponesimod stood up to Sanofi’s Aubagio (teriflunomide) in adults with relapsing multiple sclerosis. Late Thursday, Janssen said the late-stage OPTIMUM study met its primary and most secondary endpoints.